The 2-year EFS rate for IDH-inhibitor combination therapy in newly diagnosed IDH-mutated AML patients was 31% [95% CI 0.17–0.60, I2 = 84%], and the 2-year EFS rate for IDH inhibitor monotherapy in newly diagnosed IDH-mutated AML patients was not pooled due to only one relevant article. Here, IDH2 is linked to acute myeloid leukemia.